Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6922-6929

  Liu, Rong ^a,b   Curry, Stephanie ^a   McMonagle, Patricia ^a   Yeh, Wendy W ^a   Ludmerer, Steven W ^a   Jumes, Patricia A ^a   Marshall, William L ^a   Kong, Stephanie ^a,c   Ingravallo, Paul ^a   Black, Stuart ^a   Pak, Irene ^a   DiNubile, Mark J ^a   Howe, Anita Y M ^a,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b EMD Serono   (United States)

^c AB Science   (United States)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ELBASVIR; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; CLINICAL ARTICLE; FEMALE; GENOTYPE; GOOD CLINICAL PRACTICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; INHIBITORY CONCENTRATION; MALE; MONOTHERAPY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRUS RESISTANCE; WILD TYPE; ADOLESCENT; CONTROLLED STUDY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REPLICON; YOUNG ADULT;

ADOLESCENT; ADULT; BENZOFURANS; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; REPLICON; YOUNG ADULT;

EID: 84946207144     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01390-15     Document Type: Review

References (26)

1. Lawitz E, Gane E, Pearlman B., Tam E, Ghesquiere W, Guyader D., Alric L, Bronowicki JP, Lester L, Sievert W., Ghalib R, Balart L, Sund F., Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. 2015. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385:1075-1086. http://dx.doi.org/10.1016/S0140-6736(14)61795-5.
2. Sulkowski M, Hezode C, Gerstoft J., Vierling JM, Mallolas J, Pol S, Kugelmas M., Murillo A, Weis N, Nahass R., Shibolet O, Serfaty L, Bourliere M., DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. 2015. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, openlabel phase 2 trial. Lancet 385:1087-1097. http://dx.doi.org/10.1016/S0140-6736(14)61793-1.
3. Yeh W, Lipardi C, Jumes P., De Lepeleire I, Van Den Bulk N, Caro L, Huang X, Mangin E, Nachbar R, Gane E, Popa S, Ghicavii N, Wagner F, Butterton JR. 2013. MK-8742, a HCV NS5A inhibitor with a broad spectrum of HCV genotypic activity, demonstrates potent antiviral activity in genotype-1 and -3 HCV-infected patients. Hepatology 58:438A.
4. Coburn CA, Meinke PT, Chang W, Fandozzi C.M., Graham DJ, Hu B, Huang Q, Kargman S., Kozlowski J, Liu R, McCauley J.A., Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H., Zhong B, Olsen DB, Ludmerer SW. 2013. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 8:1930-1940. http://dx.doi.org/10.1002/cmdc.201300343.
5. Welsch C, Zeuzem S. 2012. Clinical relevance of HCV antiviral drug resistance. Curr Opin Virol 2:651-655. http://dx.doi.org/10.1016/j.coviro.2012.08.008.
6. American Association for the Study of Liver Diseases and Infectious Diseases Society of North America. 2015. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 29 January 2015.
7. HCV Phenotype Working Group, HCV Drug Development Advisory Group. 2015. Clinically relevant HCV drug resistance mutations figure and tables. Ann Forum Collab HIV Res 14:1-610. http://www.idsociety.org/uploadedFiles/IDSA/Hepatitis-C/For-IDSA-Members/ForumforCollaborativeHIV-ClinicallyRelevantHCVDrug.pdf. Accessed 29 January 2015.
8. Barnard RJ, Howe JA, Ogert R.A., Zeuzem S., Poordad F, Gordon SC, Ralston R, Tong X., Sniukiene V, Strizki J, Ryan D., Long J, Qiu P, Brass C.A., Albrecht J., Burroughs M, Vuocolo S, Hazuda DJ. 2013. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 444:329-336. http://dx.doi.org/10.1016/j.virol.2013.06.029.
9. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang E.Z., Spanks J., Tigges AM, Ghys A, Dorrian J, Adda N., Martin EC, Beumont M, Jacobson IM, Sherman K.E., Zeuzem S., Picchio G, Kieffer TL. 2013. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 57:221-229. http://dx.doi.org/10.1093/cid/cit226.
10. Ribeiro RM, Li H, Wang S., Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J., Parrish EH, Hahn BH, Shaw GM, Perelson A. 2012. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 8:e1002881. http://dx.doi.org/10.1371/journal.ppat.1002881.
11. Cento V, Mirabelli C, Salpini R., Dimonte S, Artese A, Costa G., Mercurio F, Svicher V, Parrotta L., Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F. 2012. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 7:e39652. http://dx.doi.org/10.1371/journal.pone.0039652.
12. Hara K, Rivera MM, Koh C, Demino M., Page S, Nagabhyru PR, Rehermann B, Liang T.J., Hoofnagle JH, Heller T. 2014. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis 209:38-45. http://dx.doi.org/10.1093/infdis/jit541.
13. Zhou S, Liu R, Baroudy B.M., Malcolm BA, Reyes GR. 2003. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310:333-342. http://dx.doi.org/10.1016/S0042-6822(03)00152-1.
14. Liu R, Abid K, Pichardo J., Pazienza V, Ingravallo P, Kong R., Agrawal S, Bogen S, Saksena A., Cheng KC, Prongay A, Njoroge FG, Baroudy B.M., Negro F. 2007. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother 59:51-58.
15. Koletzki D, Pattery T, Fevery B., Vanhooren L, Stuyver LJ. 2013. Amplification and sequencing of the hepatitis Cvirus NS3/4a protease and the NS5b polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b. Methods Mol Biol 1030:137-149. http://dx.doi.org/10.1007/978-1-62703-484-5-12.
16. Leitner T, Halapi E, Scarlatti G., Rossi P, Albert J, Fenyö EM, Uhlen M. 1993. Analysisofheterogeneous viral populationsbydirect DNA sequencing. Biotechniques 15:120-127.
17. Hernandez D, Zhou N, Ueland J., Monikowski A, McPhee F. 2013. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 57:13-18. http://dx.doi.org/10.1016/j.jcv.2012.12.020.
18. Howe AY, Black S, Curry S., Ludmerer SW, Liu R, Barnard RJ, Newhard W, Hwang P.M., Nickle D., Gilbert C, Caro L, DiNubile M.J., Mobashery N. 2014. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis 59:1657-1665. http://dx.doi.org/10.1093/cid/ciu696.
19. Xiong W, Yang J, Wang M., Wang H, Rao Z, Zhong C., Xin X, Mo L, Yu S., Shen C, Zheng C. 2015. Vinexin β interacts with hepatitis C virus NS5A, modulating its hyperphosphorylation to regulate viral propagation. J Virol 89:7385-7400. http://dx.doi.org/10.1128/JVI.00567-15.
20. Kim S, Welsch C, Yi M.K., Lemon SM. 2011. Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III. J Virol 85:6645-6656. http://dx.doi.org/10.1128/JVI.02156-10.
21. Zeuzem S, Ghalib R, Reddy K.R., Pockros PJ, Ben Ari Z, Zhao Y, Brown D.D., Wan S., DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E., Butterton JR. 2015. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163:1-13. http://dx.doi.org/10.7326/M15-0785.
22. Gao M. 2013. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 3:514-520. http://dx.doi.org/10.1016/j.coviro.2013.06.014.
23. Poordad F, Sievert W, Mollison L., Bennett M, Tse E, Bräu N, Levin J., Sepe T, Lee SS, Angus P, Conway B., Pol S, Boyer N, Bronowicki J.P., Jacobson I., Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD. 2015. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 313:1728-1735. http://dx.doi.org/10.1001/jama.2015.3860.
24. Kwo P, Gane E, Peng C-Y, Pearlman B, Vierling J., Serfaty L, Buti Ferret M, Sharfran S, Stryszak P., Lin L, Gress J, Wahl J., Barr E, Robertson M, Haber B. 2015. Efficacy and safety of grazoprevir/elbasvir +/ - RBVfor 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial, abstr P0886. In 2015 Int Liver Congress: 50th Annu Meet Eur Assoc Study Liver (EASL), Vienna, April 22 to 26, 2015.
25. Rockstroh JK, Nelson M, Katlama C., Lalezari J, Mallolas J, Bloch M., Matthews G, Saag MS, Zamor P, Orkin C., Gress J, Klopfer S, Shaughnessy M., Wahl J, Nguyen BY, Barr E, Platt H, Robertson M, Sulkowski S. 2015. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2:e319-e327. http://dx.doi.org/10.1016/S2352-3018(15)00114-9.
26. Forns X, Gordon SC, Zuckerman E, Lawitz E., Calleja JL, Hofer H, Gilbert C, Palcza J., Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E., Buti M. 2015. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 63:564-572. http://dx.doi.org/10.1016/j.jhep.2015.04.009.